Activity Overview
This online, on-demand virtual symposium brings together renowned experts in triple-negative breast cancer (TNBC). In this educational program, these experts discuss the emerging best practices in treatment, both in early-stage as well as advanced disease.
This educational activity is an archive of the live symposium held on March 7, 2026.
Target Audience
This educational activity is directed toward oncologists, advanced practice professionals, nurses, pharmacists, and other health care practitioners who manage patients with TNBC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate actionable biomarkers with tumor biology and patient-specific factors to guide individualized therapeutic decisions in early and advanced TNBC
- Assess key differences in safety profiles between current and emerging systemic therapies and implications for management of treatment-related adverse events in patients with TNBC
- Describe unique features of emerging treatments and ongoing studies to enhance clinical decision-making regarding novel agents and combination regimens in the management of TNBC
Adam Brufsky, MD, PhD
Professor of Medicine
Co-Director, Cancer Therapeutics Program
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Agendia, AstraZeneca, BriaCell, Celcuity, Daiichi Sankyo, Genentech/Roche, Gilead, Lilly, Merck, Myriad, Novartis, Pfizer, Puma, Sanofi; Ownership interests in privately held companies: Celcuity
Kamel Abou Hussein, MD
Assistant Professor of Medicine
Cooper Medical School of Rowan University
Co-Director, Janet Knowles Breast Cancer Center
Cooper University Health Care
Camden, NJ
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca; Speakers Bureau: Lilly
Priyanka Sharma, MD, FASCO
Frank B. Tyler Professor in Cancer Research
Division of Medical Oncology, Department of Internal Medicine
University of Kansas Medical Center
Co-Program Leader Drug Discovery, Delivery and Experimental
Therapeutics program
University of Kansas Cancer Center
Kansas City, KS
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Menarini Stemline, Novartis, Pfizer; Grant/Research Funding: Novartis, Gilead (funding to the institution); Royalty or Patent Benefits: UpToDate
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
